Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis

Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale

(2018) Michael Navitsky et al.   Alzheimers & Dementia

Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab

(2018) Enchi Liu et al.   NEUROLOGY

ABBY

(2018) Jeffrey L. Cummings et al.   NEUROLOGY

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

(2018) Michael F. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Amyloid Clearance as a Treatment Target Against Alzheimer's Disease

(2018) Alexander Kurz et al.   JOURNAL OF ALZHEIMERS DISEASE

Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β

(2018) Bernd Bohrmann et al.   JOURNAL OF ALZHEIMERS DISEASE

A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR

(2018) Christopher G. Schwarz et al.   JOURNAL OF ALZHEIMERS DISEASE

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

(2017) Susanne Ostrowitzki et al.   Alzheimers Research & Therapy

A simulation study on the impact of the blood flow-dependent component in [18F]AV45 SUVR in Alzheimer’s disease

(2017) Julie Ottoy et al.   PLoS One

Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials

(2016) Jeff Sevigny et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

(2016) Eric R. Siemers et al.   Alzheimers & Dementia

The amyloid hypothesis of Alzheimer's disease at 25 years

(2016) Dennis J Selkoe et al.   EMBO Molecular Medicine

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer’s disease

(2016) Mark Brody et al.   JOURNAL OF ALZHEIMERS DISEASE

Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015

(2016) Haidong Wang et al.   LANCET

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS  -amyloid in animal models and in Alzheimers disease patients

(2016) M. E. Kennedy et al.   Science Translational Medicine

The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET

(2015) William E. Klunk et al.   Alzheimers & Dementia

The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data

(2015) Mark E. Schmidt et al.   Alzheimers & Dementia

Quantification of Blood Flow-Dependent Component in Estimates of Beta-Amyloid Load Obtained Using Quasi-Steady-State Standardized Uptake Value Ratio

(2015) Zsolt Cselényi et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Partial volume correction in quantitative amyloid imaging

(2015) Yi Su et al.   NEUROIMAGE

Longitudinal Amyloid Imaging Using 11C-PiB: Methodologic Considerations

(2013) B. N. M. van Berckel et al.   JOURNAL OF NUCLEAR MEDICINE

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

(2013) Victor L Villemagne et al.   LANCET NEUROLOGY

New and emerging treatments for Alzheimer’s disease

(2012) Anne Corbett et al.   Expert Review of Neurotherapeutics

Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects

(2012) A. D. Joshi et al.   JOURNAL OF NUCLEAR MEDICINE

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

(2012) Christopher M Clark et al.   LANCET NEUROLOGY

The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes

(2012) Iryna Benilova et al.   NATURE NEUROSCIENCE

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Soluble forms of tau are toxic in Alzheimer’s disease

(2012) Katherine Kopeikina et al.   Translational Neuroscience

Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease

(2011) Adam S. Fleisher   ARCHIVES OF NEUROLOGY

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

(2011) Susanne Ostrowitzki   ARCHIVES OF NEUROLOGY

The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease

(2011) Benjamin A. Thomas et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

(2011) Christopher M. Clark   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study

(2011) Henryk Barthel et al.   LANCET NEUROLOGY

Current Treatment and Recent Clinical Research in Alzheimer's Disease

(2010) Judith Neugroschl et al.   MOUNT SINAI JOURNAL OF MEDICINE